MetrioPharm AG was set up by scientists, innovative thinkers and investors with the collaboration of Swiss Athenion AG to take on the further development and marketing of therapies against bacterial and viral infections on the basis of innovative advanced pharmaceutical drugs of the category of MP 1000.
MetrioPharm AG is engaged in the development, clinical research and worldwide marketing of therapeutical treatments based on the enterprises own patented medicine.
Our innovative medicines are to use in the treatment of various wide spread infectious diseases, the majority of them very life-threatening. There aren't any effective therapies for many of these deseases available today. Clinical studies have proven the safety and effectiveness of our medicines based on the patented drug MP1021. Based on these results the medicins have been approved for commercial usage in various countries.